HC Wainwright Comments on Nkarta’s Q4 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Stock analysts at HC Wainwright issued their Q4 2025 earnings per share estimates for shares of Nkarta in a research report issued on Thursday, March 27th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s FY2029 earnings at ($0.99) EPS.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06.

NKTX has been the subject of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Nkarta in a research note on Thursday. Stifel Nicolaus decreased their target price on Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Nkarta currently has a consensus rating of “Buy” and an average price target of $14.86.

Nkarta Price Performance

Shares of NKTX opened at $1.97 on Friday. Nkarta has a one year low of $1.31 and a one year high of $11.84. The company has a 50-day moving average of $2.00 and a two-hundred day moving average of $2.89. The stock has a market cap of $139.02 million, a price-to-earnings ratio of -1.05 and a beta of 0.90.

Institutional Investors Weigh In On Nkarta

Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN lifted its stake in Nkarta by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 31,056 shares of the company’s stock valued at $77,000 after acquiring an additional 6,763 shares during the last quarter. Catalina Capital Group LLC raised its holdings in shares of Nkarta by 57.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock valued at $47,000 after purchasing an additional 6,867 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock valued at $60,000 after purchasing an additional 7,030 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Nkarta in the third quarter worth $33,000. Finally, American Century Companies Inc. increased its position in Nkarta by 8.8% during the fourth quarter. American Century Companies Inc. now owns 90,952 shares of the company’s stock worth $226,000 after buying an additional 7,378 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the transaction, the chief executive officer now owns 319,859 shares in the company, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 8.70% of the stock is currently owned by company insiders.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.